SUPPLEMENTARY INFORMATION: The Agency requests nominations for
nonvoting industry representatives on the Tobacco Products Scientific
Advisory Committee.

I. Tobacco Products Scientific Advisory Committee

The Tobacco Products Scientific Advisory Committee (the Committee)
advises the Commissioner of Food and Drugs (the Commissioner) or designee in
discharging responsibilities as they relate to the regulation of tobacco
products. The Committee reviews and evaluates safety, dependence, and
health issues relating to tobacco products and provides appropriate
advice, information, and recommendations to the Commissioner.
The Committee includes three nonvoting members who represent
industry interests. These members include one representative of the
tobacco manufacturing industry, one representative of the interests of tobacco
growers, and one representative of the interests of the small business tobacco
manufacturing industry. The representative of the interests of the small
business tobacco manufacturing industry may be filled on a rotating,
sequential basis by representatives of different small business tobacco
manufacturers based on areas of expertise relevant to the topics being
considered by the Committee.

With this notice, nominations are sought for the following positions: (1)
One representative of the interests of tobacco growers, and an alternate to
this representative; (2) a pool of individuals, with varying areas of expertise, to
represent the interests of the small business tobacco manufacturing
industry on a rotating, sequential basis; and (3) an individual to serve as
alternate to the representative of the tobacco manufacturing industry.

II. Selection Procedure

Any industry organization interested in participating in the selection of
appropriate nonvoting member(s) to represent industry interests should send
a letter stating that interest to the FDA contact (see FOR FURTHER INFORMATION
CONTACT and DATES). Within the subsequent 30 days, FDA will send a
letter to each organization that has expressed an interest, attaching a
complete list of all such organizations, and a list of all nominees along with
their current resumes. The letter will also state that it is the responsibility of
the interested organizations to confer with one another and to select a
candidate, within 60 days after the receipt of the letter, to serve as the
nonvoting member to represent industry interests on the Committee. The
interested organizations are not bound by the list of nominees in selecting a
candidate. However, if no individual is selected within 60 days, the
Commissioner will select the nonvoting member to represent the industry
interests.

III. Application Procedure

Individuals may self-nominate and/or organizations may nominate one or
more individuals to serve as a nonvoting industry representative (for the roles
specified in this document). Nominations must include a current
resume or curriculum vitae of the nominee including current business
address and/or home address, telephone number, e-mail address if available, and
the role for which the individual is being nominated. Nominations must
also acknowledge that the nominee is aware of the nomination unless self-
nominated. FDA will forward all nominations to the organizations
expressing interest in participating in the selection process for the committee.
(Residents who nominate themselves as nonvoting industry representatives will
not participate in the selection process.)

FDA has a special interest in ensuring that women, minority groups, and
individuals with physical disabilities are adequately represented on its
advisory committees and, therefore, encourages nominations for
appropriately qualified candidates from these groups.

This notice is issued under the Federal Advisory Committee Act (5 U.S.C. app. 2) and 21 CFR part 14,
relating to advisory committees. (Persons who nominate themselves as
nonvoting industry representatives will not participate in the selection process.)

Pursuant to section 10(d) of the Federal Advisory Committee Act, as
amended (5 U.S.C. App.), notice is hereby given of the following meetings.
The meetings will be closed to the public in accordance with the
provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and the discussions could disclose
confidential trade secrets or commercial property such as patentable material,
and personal information concerning individuals associated with the grant
applications, the disclosure of which would constitute a clearly unwarranted
invasion of personal privacy.

Name of Committee: National Institute of Allergy and Infectious Diseases Special
Date: October 3, 2011.
Time: 1 p.m. to 5 p.m.
Agenda: To review and evaluate contract proposals.
Place: National Institutes of Health, 6700B
Rockledge Drive, Bethesda, MD 20817.
(Telephone Conference Call).
Contact Person: Brandt R. Burgess, PhD,
Scientific Review Officer, Scientific Review
Program, Division of Extramural Activities,
DHHS/NIAID, 6700B Rockledge Drive,
MSC 7616, Bethesda, MD 20892–7616, (301)
451–2584, bburgess@niaid.nih.gov.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.853, Allergy, Immunology,
and Transplantation Research; 93.856,
Microbiology and Infectious Diseases
Research, National Institutes of Health, HHS)
Dated: September 6, 2011.
Jennifer S. Spaeth,
Director, Office of Federal Advisory
Committee Policy.
[FR Doc. 2011–23231 Filed 9–9–11; 8:45 am]
BILLING CODE 4140–01–P

DEPARTMENT OF HEALTH AND
HUMAN SERVICES

National Institutes of Health

National Institute of Diabetes and
Digestive and Kidney Diseases
Notice of Closed Meetings

Pursuant to section 10(d) of the Federal Advisory Committee Act, as
amended (5 U.S.C. App.), notice is hereby given of the following meetings.
The meetings will be closed to the public in accordance with the
provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and the discussions could disclose
confidential trade secrets or commercial property such as patentable material,
and personal information concerning individuals associated with the grant
applications, the disclosure of which would constitute a clearly unwarranted
invasion of personal privacy.

Name of Committee: National Institute of
Diabetes and Digestive and Kidney Diseases
Special Emphasis Panel; The NIDDK–KUH Fellowship Review.
Date: October 6, 2011.
Time: 9 a.m. to 12 p.m.